NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Scholar Rock Holding Corp. SRRK
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-3.29
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-123.1%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 9-year series below
Revenue
Net income
Per share
USD -3.29
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-123.1%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-86.0%
Each USD of equity lost 123 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+217.6%
Change, 10 years—
The share count grew 218% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 404.3M
total assets, end of FY2025
Total assetsUSD 404.3M
EquityUSD 245.5M
CashUSD 323.5M
Gross debtUSD 99.7M
Net debtUSD -223.8M
Current ratio6.95×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
·
·
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.4
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
Net income $B
−0.4
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−3.29
−2.47
−1.99
−2.26
−3.59
−2.81
−1.85
−3.15
−15.30
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−123.1
−82.9
−68.3
−62.2
−60.9
−46.3
−46.5
−185.8
·
Shares out B
0.11
0.09
0.08
0.05
0.04
0.03
0.03
0.03
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed